Literature DB >> 20367770

Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation.

Stanley E Althof1, Gerald B Brock2, Raymond C Rosen3, David L Rowland4, Joseph W Aquilina5, Margaret Rothman6, Fisseha Tesfaye5, Scott Bull5.   

Abstract

INTRODUCTION: The Clinical Global Impression of Change (CGIC) measures have high utility in clinical practice. However, it is unknown whether the CGIC is valued for assessing premature ejaculation (PE) symptoms and/or the relationship between CGIC and other validated PE patient-reported measures. AIM: The study aims to assess the validity of the patient-reported CGIC measure in men with PE and to examine the relationship between CGIC ratings and assessments of control, satisfaction, personal distress, and interpersonal difficulty.
METHODS: Data from a randomized, double-blind, 24-week phase 3 trial in 1,162 men with PE who received dapoxetine (30 mg or 60 mg) or placebo on demand provided the basis for the analysis. Patients were ≥18 years, in a stable monogamous relationship for ≥6 months, met the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision criteria for PE for ≥6 months, and had an intravaginal ejaculatory latency time (IELT) ≤2 minutes in ≥75% of intercourse episodes. MAIN OUTCOME MEASURES: The CGIC asked patients to rate improvement or worsening of their PE compared with the start of the study using a 7-point response scale; other patient-reported measures were control over ejaculation, satisfaction with sexual intercourse, interpersonal difficulty, and personal distress related to ejaculation. Stopwatch-measured IELT was recorded. Associations between CGIC and change in other measures at study end point were assessed.
RESULTS: The magnitude of IELT increased for each category of improvement on the CGIC: 1.63, 4.03, and 7.15 minutes for slightly better, better, and much better, respectively. Higher CGIC ratings were correlated with greater improvement in control (r = 0.73), satisfaction (r = 0.62), greater reduction in distress (r = -0.52), and interpersonal difficulty (r = -0.39). Total variance accounted for was 57.4%: control (48.7%), satisfaction (4.5%), IELT (2.8%), and distress (1.15%).
CONCLUSIONS: The analyses support the validity of the CGIC measure in men with PE. The CGIC can provide clinicians in practice with a valid and brief outcome assessment of their patient's condition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367770     DOI: 10.1111/j.1743-6109.2010.01793.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

1.  Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation.

Authors:  Ej McCarty; Ww Dinsmore
Journal:  Core Evid       Date:  2012-01-19

2.  Selective serotonin re-uptake inhibitors for premature ejaculation in adult men.

Authors:  Niranjan J Sathianathen; Eu Chang Hwang; Ruma Mian; Joshua A Bodie; Ayman Soubra; Jennifer A Lyon; Shahnaz Sultan; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-03-21

Review 3.  The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation.

Authors:  Cao De Hong; Liu Liang Ren; Huang Yu; Wei Qiang
Journal:  Sci Rep       Date:  2014-12-01       Impact factor: 4.379

4.  Effectiveness of 'on demand' silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study.

Authors:  Gajanan S Bhat; Anuradha Shastry
Journal:  Cent European J Urol       Date:  2016-07-08

5.  The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy: The PASSION Study.

Authors:  Chris McMahon; Sung Won Lee; Sae Woong Kim; Du Geon Moon; Apichat Kongkanand; Kavirach Tantiwongse
Journal:  Sex Med       Date:  2016-03       Impact factor: 2.491

Review 6.  The design and methodology of premature ejaculation interventional studies.

Authors:  Chris G McMahon
Journal:  Transl Androl Urol       Date:  2016-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.